LONG BEACH, Calif. — In this video, John W. Kitchens, MD, discusses a session presented at the American Society of Retina Specialists annual meeting about real-world utilization of the aflibercept biosimilar Pavblu.Pavblu (aflibercept-ayyh, Amgen) in 2024 as a biosimilar to Eylea (aflibercept, Regeneron).
“It’s great to have real-world studies that are reassuring,” Kitchens, of Retina Associates of Kentucky, told Healio.